RXi Pharma breaks downtrend, up 23%
Seeking Alpha
Published Jul 10, 2018 03:30PM ET
RXi Pharma breaks downtrend, up 23%
- Thinly traded nano cap RXi Pharmaceuticals (RXII +22.8%) is up on almost a 4x surge in volume. Shares had been in a downtrend since a brief rally in March, shedding 70% of their value since touching $6.76 on March 15.
- This morning, collaboration partner BioAxone BioSciences announced that the National Institute of Neurological Disorders and Stroke awarded it a $1.1M grant to fund the continued development of BA-434 for the treatment of spinal cord injury. RXi will receive ~$119K of the award for its contribution.
- On the capital front, RXi had $2.6M in cash at the end of March while operations consumed $1.9M during the quarter. In April, the company executed a stock offering that raised net proceeds of $4.1M. Operations consumed an average of $2.4M of cash per quarter in 2017 so more capital will be needed before year-end.
- Now read: Your Daily Pharma Scoop: Abeona Presents Strong Data, Glaxo Nucala Treatment Benefit, Rocket Pharma's Gene Therapy Data
Original article
Get The News You Want
Written By: Seeking Alpha
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.